Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions (POWERFUL)

10 mai 2021 mis à jour par: Genesis Pharma S.A.

A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in Relapsed/ ReFractory Multiple Myeloma Patients Under Real-Life Conditions,

The importance of real-world evidence studies stems from the following considerations. The study population of a specific clinical trial needs to meet strict inclusion and exclusion criteria, which result in a population of participants that is not necessarily representative of the study population of interest treated in routine care. Furthermore, the outcomes of a clinical trial occur under controlled conditions that do not necessarily reflect the routine healthcare practice. This is especially true among patient populations with challenging to treat disease such as in MM, where personalized therapeutic approaches are commonly considered taking into consideration the patients' age and associated comorbidities, among other factors. In addition, observational studies, due to their non-interventional nature, often show increased degree of heterogeneity across the enrolled patient populations compared to clinical studies, thus aiding generalizability of the results.

In light of the above and due to the scarcity of evidence regarding the outcomes for patients with RRMM receiving Pom/LoDex in routine clinical practice, this retrospective chart review and prospective observational study aims to assess the PFS and response to treatment as well as to obtain real-world evidence on the utilization patterns and management strategy of Pom/LoDex in routine clinical care settings in Greece.

This is a non-interventional, multicenter, single-country, retrospective chart review and prospective cohort study which will include a representative sample of patients with RRMM who have been initiated on Pom/LoDex between 01 January 2016 and 28 February 2019 in the third line and beyond treatment setting under routine care conditions in Greece.

The study will be carried out by hospital-based hematology specialists practicing in geographically diverse locations throughout Greece and will be conducted under real-world conditions of daily clinical practice.

Aperçu de l'étude

Statut

Complété

Les conditions

Type d'étude

Observationnel

Inscription (Réel)

110

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Patra, Grèce
        • Ag.Andreas General Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

A total of 100 adult patients with RRMM who have been initiated on Pom/LoDex treatment as indicated in the product's Summary of Product Characteristics (SmPC) (i.e., after having received at least two prior therapies including both lenalidomide and bortezomib and whose disease progressed after the last treatment) between 01 January 2016 and 28 February 2019 and who are eligible for participation in the study according to the inclusion and exclusion criteria -as outlined in Section 10- are planned to be recruited in the present clinical study. For the justification of the sample size please refer to Section 13.1.

La description

  • Patients eligible for inclusion in this study have to meet all of the following criteria:

    • Adult subjects (aged ≥18 years) of either gender.
    • Subjects with a documented RRMM diagnosis according to IMWG or EBMT criteria prior to Pom/LoDex treatment.
    • Subjects who have been initiated on Pom/LoDex treatment as per the product's Summary of Product Characteristics (SmPC) between 01 January 2016 and 28 February 2019, after having received at least two prior therapies including both lenalidomide and bortezomib and whose disease progressed after the last treatment.*
    • Note: Retrospective patients who at the time of their enrollment in the study have already completed 3 or more cycles with Pom/LoDex must have available at least one post-baseline response assessment
    • Subjects with available medical files/records and detailed historical data on their disease course and clinical management.
    • Provision of signed informed consent form (ICF) for collecting and analyzing medical data pertinent to the objectives of this study.**

      • Note: For retrospective subjects who are deceased at the date of enrollment into the study a waiver of consent will be requested by the Hospital Scientific Committee and/or Administrative Board of each participating site to either implement a hospital ICF already in place or provide written approval of this study- specific waiver. In the occasion that waiver of consent is not granted by the Scientific Committee and/or Administrative Board of the study site, deceased subjects will not be enrolled in the study.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from participation in this study:

  • Prior malignancy (within the 3 years preceding initial diagnosis of MM).
  • Concurrent administration of anti-cancer regimens for malignancies other than MM.
  • Subjects currently participating or who have participated, during the treatment phase, in any investigational program with interventions outside of routine clinical practice.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Effectiveness of Pom/LoDex in terms of median PFS
Délai: median time from start of Pom/LoDex treatment to disease progression or death, through study completion and maximum 50 months
To evaluate the effectiveness of Pom/LoDex in terms of median PFS, in eligible patients with RRMM in a real world setting in Greece.
median time from start of Pom/LoDex treatment to disease progression or death, through study completion and maximum 50 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Response to Pom/LoDex treatment in terms of ORR
Délai: from start of Pom/LoDex until achievement of PR or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of ORR in the study RRMM population
from start of Pom/LoDex until achievement of PR or better, through study completion and maximum 50 months
Response to Pom/LoDex treatment in terms of CBR
Délai: from start of Pom/LoDex until achievement of MR or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of clinical benefit rate (CBR) in the study RRMM population
from start of Pom/LoDex until achievement of MR or better, through study completion and maximum 50 months
Response to Pom/LoDex treatment in terms of DCR
Délai: from start of Pom/LoDex until achievement of SD or better, through study completion and maximum 50 months
To estimate the response to Pom/LoDex treatment in terms of disease control rate (DCR) in the study RRMM population
from start of Pom/LoDex until achievement of SD or better, through study completion and maximum 50 months
TTR among the RRMM study population who achieved at least partial response (PR)
Délai: median from start of Pom/LoDex to first documented response (TTR), through study completion and maximum 50 months
To estimate time to response (TTR) to Pom/LoDex among the RRMM study population who achieved at least partial response (PR);
median from start of Pom/LoDex to first documented response (TTR), through study completion and maximum 50 months
DoR among the RRMM study population who achieved at least partial response (PR)
Délai: median from start of Pom/LoDex to first disease progrestion or death (DoR), through study completion and maximum 50 months
To estimate duration of response (DoR) to Pom/LoDex among the RRMM study population who achieved at least partial response (PR);
median from start of Pom/LoDex to first disease progrestion or death (DoR), through study completion and maximum 50 months
12-month PFS rate
Délai: time from start of Pom/LoDex until 12 months
To evaluate the 12-month PFS rate under treatment with Pom/LoDex in the RRMM study population
time from start of Pom/LoDex until 12 months
Time to progression
Délai: median time from start of Pom/LoDex until disease progression or death, through study completion and maximum 50 months
To estimate time to progression (TTP) under treatment with Pom/LoDex in the RRMM study population
median time from start of Pom/LoDex until disease progression or death, through study completion and maximum 50 months
Real-world utilization patterns of Pom/LoDex in the RRMM study population
Délai: no time frame - only proportion of patients in 12 month follow-up
To capture the real-world utilization patterns of Pom/LoDex in the RRMM study population, in terms of the rate of its incorporation in the third versus a later-line therapeutic strategy, and the prior treatment modalities employed in real-life clinical practice
no time frame - only proportion of patients in 12 month follow-up

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Evaluate the effectiveness and response to Pom/LoDex treatment in the subpopulations of RRMM patients who have been initiated on Pom/LoDex in the third line versus later line setting
Délai: from start of Pom/LoDex until 12 month follow-up
Separation of Pom/Dex treatment outcomes in two subgroups of patients (treated in the third line versus later lines)
from start of Pom/LoDex until 12 month follow-up
To evaluate the improvement of the QoR with Pom/LoDex continued treatment
Délai: from start of Pom/LoDex until 12 month follow-up
To measure the improvement of the quality of response with Pom/LoDex continued treatment over time (i.e. improvement from PR to VGPR)
from start of Pom/LoDex until 12 month follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Kiki Karvounis, Genesis Pharma S.A.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 novembre 2017

Achèvement primaire (Réel)

21 février 2020

Achèvement de l'étude (Réel)

28 février 2020

Dates d'inscription aux études

Première soumission

31 octobre 2017

Première soumission répondant aux critères de contrôle qualité

20 novembre 2017

Première publication (Réel)

27 novembre 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 mai 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 mai 2021

Dernière vérification

1 mai 2021

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NIS-GEN-POM-001

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .